EUCTR2010-019955-23-GB进行中（未招募）不适用
To evaluate the pharmakcokinetics, tolerability and short term safety of ciprofloxacin in neonates and infants with suspected (or proven) Gram Negative Infection Open Label pilot PK study - TINN Treat Infections in Neonates Program(TINN-PK) - TINN Treat Infections in Neonates Pharmocokinetics of Ciprofloxacin
iverpool Women's NHS Foundation Trust0 个研究点开始时间: 2010年11月26日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Neonates and infants 24 - 52 weeks gestation who are receiving ciprofloxacin following a clinical decision by their attending physician to treat suspected or proven sepsis.
- •Parental consent to participate
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years)
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Likely not to survive for more than 48 hours in judgement of attending physician.
- •Significant liver or renal impairment.
研究者
相似试验
进行中（未招募）
1 期
Investigating the DopaFuse® Delivery System in Parkinson's Disease Patients. Assessing safety, effectiveness, how well it is tolerated, and how the drug is processed by the body.EUCTR2020-003372-41-ITSynAgile Corporation24
进行中（未招募）
1 期
Investigating the DopaFuse® Delivery System in Parkinson’s Disease Patients. Assessing safety, effectiveness, how well it is tolerated, and how the drug is processed by the body.Motor symptoms in Parkinson’s Disease.MedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-003372-41-ESSynAgile Corporation24
进行中（未招募）
1 期
Evaluation of the Pharmacokinetics, Safety, Tolerability and Efficacy of Entecavir (ETV)in Pediatric Subjects with Chronic Hepatitis B Virus (HBV) Infection who are HBeAg-Positive. Revised Protocol 02, incorporating Protocol Amendment 01 (v1.0, date 18-Apr-2008), and Protocol Amendment 04 (v1.0, date 05-Dec-2008).Chronic Hepatitis B Virus (HBV) InfectionMedDRA version: 8.1Level: LLTClassification code 10019743Term: Hepatitis B virus (HBV)EUCTR2005-005816-26-BEBristol-Myers Squibb International Corporation64
进行中（未招募）
1 期
A study of Entecavir in Pediatric Patients with Chronic Hepatitis B Virus (HBV) InfectioChronic Hepatitis B Virus (HBV) InfectionMedDRA version: 16.1 Level: LLT Classification code 10019743 Term: Hepatitis B virus (HBV) System Organ Class: 100000004848EUCTR2005-005816-26-GBBristol-Myers Squibb International Corporation64
进行中（未招募）
不适用
A study of Entecavir in Pediatric Patients with Chronic Hepatitis B Virus (HBV) InfectioEUCTR2005-005816-26-Outside-EU/EEABristol-Myers Squibb International Corporation64